Short Interest in Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Drops By 20.7%

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the recipient of a large decrease in short interest in the month of October. As of October 15th, there was short interest totalling 76,800 shares, a decrease of 20.7% from the September 30th total of 96,900 shares. Based on an average trading volume of 1,069,300 shares, the days-to-cover ratio is presently 0.1 days.

Bayer Aktiengesellschaft Stock Up 0.1 %

BAYRY traded up $0.01 on Monday, reaching $6.99. The company’s stock had a trading volume of 961,900 shares, compared to its average volume of 1,340,280. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.27 and a quick ratio of 0.86. Bayer Aktiengesellschaft has a 1 year low of $6.82 and a 1 year high of $11.34. The business’s 50 day moving average is $7.71 and its 200 day moving average is $7.48. The stock has a market cap of $27.47 billion, a price-to-earnings ratio of -8.03 and a beta of 1.08.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.25 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.25. The business had revenue of $12 billion during the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.74% and a positive return on equity of 16.96%. As a group, research analysts forecast that Bayer Aktiengesellschaft will post 1.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Bank of America raised shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research report on Friday, September 6th. One investment analyst has rated the stock with a sell rating and eight have given a hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.